PACK NO. 05
The new medicine
The two companies behind the appetite drugs.
Eli LillyEli LillyLLY · 50%
Novo NordiskNovo NordiskNVO · 50%
Interest down 9% this week10k Wikipedia reads about these companies
Tokenized stocks that track the real share price, bought into your own wallet. They can lose value.
The idea
Appetite medicine becomes everyday healthcare
Metabolic medicines that change appetite are moving from a niche prescription toward routine care. If access, supply and delivery keep improving, the treatment market grows with them.
Why these two
- Eli Lilly
Eli LillyThe broadest pipeline · 50%
Eli Lilly sells leading metabolic medicines and publishes a deep pipeline in the same field, so it gains if the market widens beyond today's patients.
- Novo Nordisk
Novo NordiskThe first mover · 50%
Novo Nordisk built the category and holds the cardiovascular indication the FDA approved, which is the clearest step from weight loss toward everyday care.
The other side
A bigger market can come with lower prices. Governments and insurers push net prices down, many patients stop treatment within a year, competitors and cheaper copies arrive, and a safety finding could change everything. Both companies are already priced for a lot of this growth, so patients can multiply while shareholders earn little.
What would change the call
Across the next two earnings cycles, prescriptions keep rising while net prices and the share of patients who stay on treatment both fall; or a material safety or regulatory setback for the class.
Record: these holdings at these weights, held from Sep 30, 2025 to Sep 29, 2026, from daily closing prices, before fees. “Live” is the thesis’s public record since its call opened on Sep 25, 2026. “Interest” is human page views of each company’s English Wikipedia article, the last 7 days against the 7 before. Past performance isn’t a promise.
Sources and version history